Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection Amid Financial Struggles
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Bankruptcy Filing: Biotech firm Sangamo Therapeutics filed for Chapter 11 bankruptcy protection in Delaware on Tuesday, with assets and liabilities estimated between $100 million and $500 million, indicating a significant deterioration in its financial condition.
- Financial Advisor Appointment: The company recently retained Raymond James as its financial advisor to evaluate a full range of strategic alternatives aimed at advancing its promising pipeline and maximizing value for all stakeholders amidst financial challenges.
- Pipeline Prospects: Sangamo anticipates completing the Biologics License Application (BLA) submission for ST-920 as early as this summer, indicating ongoing efforts to advance its key product development despite financial difficulties.
- NASDAQ Delisting Appeal: The company also plans to appeal the NASDAQ delisting decision in June, demonstrating its determination to remain active in the capital markets despite its current challenges.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
